Key Takeaway
Which Glp-1 Is Best for Diabetes and Weight Loss. Evidence-based answers from FormBlends, a physician-supervised telehealth weight loss clinic.
Tirzepatide shows the strongest weight loss results at 21% body weight reduction in the SURMOUNT-1 trial, while semaglutide 2.4mg achieved 15% weight loss in STEP trials. Liraglutide produces 8% weight loss but requires daily injections. For diabetes, all three medications improve HbA1c by 1.5-2.3 percentage points[4], with tirzepatide showing superior glucose control.
Here is what the current medical evidence says about which GLP-1 is best for diabetes and weight loss. At FormBlends, our physicians stay on top of the latest research to give patients clear, actionable information. Below we break down what you need to know, based on clinical data and our clinical experience.What Does the Research Say About Which Glp-1 Is Best for Diabetes and Weight Loss?
The medical literature on which GLP-1 is best for diabetes and weight loss provides several key findings:
- GLP-1 receptor agonists work by mimicking natural gut hormones that regulate appetite and blood sugar
- Clinical trials have shown consistent weight loss results across diverse patient populations
- Side effects are primarily gastrointestinal and tend to improve during the first weeks of treatment
- Physician supervision is important for monitoring progress and adjusting dosing
How Does This Apply to Your Treatment?
Understanding which GLP-1 is best for diabetes and weight loss matters because it directly affects treatment decisions. At FormBlends, our physicians consider this information when building your personalized protocol. Every patient is different, and what works for one person may need adjustment for another.
View data table
| Category | Search Volume Share (%) | Detail |
|---|---|---|
| Side Effects | 35 | Nausea, GI issues |
| Cost/Insurance | 28 | Pricing questions |
| Effectiveness | 22 | How much weight loss |
| Eligibility | 15 | BMI requirements |
We recommend discussing which GLP-1 is best for diabetes and weight loss with your FormBlends physician during your consultation. They can explain how it applies to your specific health history and weight loss goals.
Clinical Evidence
The SURMOUNT-1 trial[1] demonstrated tirzepatide 15mg achieved 21% weight loss over 72 weeks in 2,539 patients[1] without diabetes. Semaglutide 2.4mg produced 15% weight loss in the STEP-1 trial[2] with 1,961 participants[2] over 68 weeks. Liraglutide 3mg showed 8% weight loss in SCALE obesity[3] trials but requires daily subcutaneous injection versus weekly dosing for tirzepatide and semaglutide.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for physician-supervised GLP-1 therapy.
Try the BMI Calculator →For diabetes management, tirzepatide reduced HbA1c by 2.3 percentage points[4] in SURPASS trials, outperforming semaglutide's 1.5-2.0 percentage point reduction. All three medications delay gastric emptying by 70-80 minutes, contributing to appetite suppression. Nausea affects 20-44% of patients across all agents, typically resolving within 4-8 weeks. Treatment discontinuation rates range from 15-25% primarily due to gastrointestinal intolerance during dose escalation phases.
Clinical Evidence
SURMOUNT-1 data shows tirzepatide achieves 21% weight loss compared to semaglutide's 15% in STEP trials. Both medications demonstrate superior diabetes control with HbA1c reductions of 1.5-2.3 percentage points[4] across multiple phase 3 studies.
What Should You Do Next?
If you have questions about which GLP-1 is best for diabetes and weight loss, FormBlends can help. Our licensed physicians provide personalized guidance based on your medical history and goals. Start with a free online evaluation to connect with a provider who can answer your specific questions.
- Semaglutide for weight loss
- Tirzepatide for weight loss
- Compounded GLP-1 medications
Medical References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. [PubMed | ClinicalTrials.gov | DOI]
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. [PubMed | ClinicalTrials.gov | DOI]
- Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. [PubMed | DOI]
Get Personalized Answers
General information is a starting point, but your treatment should be tailored to you. FormBlends connects you with licensed physicians who can evaluate your situation and provide specific recommendations. Complete your free evaluation today.